# Good Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/good-therapeutics

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.goodtherapeutics.com
- Total disclosed funding: $31M
- Latest round: Series B (Dec 8, 2021)
- Investors on record: 5

## About

Good Therapeutics, Inc. focuses on developing innovative protein therapeutics designed to enhance targeted biological activity, primarily in oncology and autoimmune diseases, aiming to improve treatment effectiveness and safety.Founded in 2016, Good Therapeutics, Inc. is based in Seattle, US, and specializes in creating regulated protein therapeutics. The company was recently acquired in September 2022 by F. Hoffmann-La Roche Ltd for USD 250 mn, marking a significant shift in their operational strategy. The acquisition is set to enhance Good Therapeutics' capabilities in immuno-oncology. The company has completed a total of 4 deals since its inception. With a focus on advancing its proprietary technology, Good Therapeutics has also attracted notable investors including 3x5 Partners, Digitalis Ventures, RiverVest Ventures, and Roche Venture Fund.Good Therapeutics, Inc. develops a novel class of regulated protein therapeutics, particularly focusing on antibody-controlled cytokines that enhance the anti-tumor immune response. Their innovative therapeutics remain inactive until they bind to specific targets, allowing for precise regulation of activity. The primary applications are in oncology, with potential extensions into autoimmune diseases, metabolic disorders, and pain management. The company is currently in the preclinical development stages, targeting markets in North America, Europe, and Asia, addressing the demand for safer and more effective treatments.Good Therapeutics, Inc. generates revenue through partnerships and collaborations with research institutions and pharmaceutical companies in the B2B sector. Revenue streams are driven by licensing agreements and milestone payments linked to the advancement of their therapeutic programs. Their flagship products, centered on the antibody-controlled cytokine platform, will be pivotal for revenue generation as they move through clinical phases toward market readiness, with transaction structures tailored to maximize stakeholder value.The acquisition by Roche is expected to close in the third quarter of 2022, providing Good Therapeutics with substantial resources to advance its product pipeline. Following this transaction, the focus will be on integrating their active therapeutics with Roche’s immuno-oncology targets. Upcoming product launches are anticipated to leverage this integration to enhance treatment options in oncology. The company aims to expand its market presence in North America, Europe, and Asia, with plans to accelerate the development and commercialization of their innovative therapeutics, utilizing the recent USD 250 mn funding to support these initiatives.

## Funding rounds

- Series B, Dec 8, 2021, $8.8M — RiverVest Ventures Partners, Roche Venture Fund, 503 Partners, Digitalis Ventures
- Series A, May 21, 2020, $11M — RiverVest Ventures Partners, Roche Venture Fund, 503 Partners, Digitalis Ventures, Codon Capital
- Series A, Jan 31, 2019, $11M — RiverVest Ventures Partners, Roche Venture Fund, 503 Partners, Digitalis Ventures

## Investors

- RiverVest Ventures Partners (https://capitalatlas.ai/funds/rivervest-ventures-partners) — Series A, Series B
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series A, Series B
- 503 Partners (https://capitalatlas.ai/funds/503-partners) — Series A, Series B
- Digitalis Ventures (https://capitalatlas.ai/funds/digitalis-ventures) — Series A, Series B
- Codon Capital (https://capitalatlas.ai/funds/codon-capital) — Series A